In what may prove to be a tipping point for prosecutions against pharmaceutical companies, states are beginning to see their “enforcement efforts pay for themselves,” according to an article yesterday in Pharmalot. A report by Public Citizen details more than $10 billion in financial penalties awarded against pharmaceuticals from November 2011 to July 2012, and attributes the spate to the initiative of individual state attorneys general and, most importantly, the whistleblower provisions of the federal False Claims Act.
Of further interest:
State Settlements With Drug Companies Over Medicaid Fraud Are at Record Highs; Many States Recover More Than They Spent on Enforcement